NO983636L - FremgangsmÕte for behandling av brekninger og sykdomstilstander i sentralnervesystemet ved anvendelse av optisk rent (+) norcisaprid - Google Patents

FremgangsmÕte for behandling av brekninger og sykdomstilstander i sentralnervesystemet ved anvendelse av optisk rent (+) norcisaprid

Info

Publication number
NO983636L
NO983636L NO983636A NO983636A NO983636L NO 983636 L NO983636 L NO 983636L NO 983636 A NO983636 A NO 983636A NO 983636 A NO983636 A NO 983636A NO 983636 L NO983636 L NO 983636L
Authority
NO
Norway
Prior art keywords
norcisapride
treatment
nervous system
central nervous
optically pure
Prior art date
Application number
NO983636A
Other languages
English (en)
Other versions
NO983636D0 (no
NO317178B1 (no
Inventor
John R Mccullough
Thomas P Jerussi
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Publication of NO983636D0 publication Critical patent/NO983636D0/no
Publication of NO983636L publication Critical patent/NO983636L/no
Publication of NO317178B1 publication Critical patent/NO317178B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO19983636A 1996-07-19 1998-08-07 Anvendelse av (+) norcisaprid for fremstilling av medikamenter samt farmasoytisk preparat og enhetsdoseform omfattende forbindelsen NO317178B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/684,753 US5739151A (en) 1996-07-19 1996-07-19 Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
PCT/US1997/011629 WO1998003173A1 (en) 1996-07-19 1997-07-02 Methods for treating emesis and central nervous system disorders using optically pure (+) norcisapride

Publications (3)

Publication Number Publication Date
NO983636D0 NO983636D0 (no) 1998-08-07
NO983636L true NO983636L (no) 1998-10-19
NO317178B1 NO317178B1 (no) 2004-09-06

Family

ID=24749413

Family Applications (2)

Application Number Title Priority Date Filing Date
NO19983636A NO317178B1 (no) 1996-07-19 1998-08-07 Anvendelse av (+) norcisaprid for fremstilling av medikamenter samt farmasoytisk preparat og enhetsdoseform omfattende forbindelsen
NO20041166A NO20041166L (no) 1996-07-19 2004-03-19 Anvendelse av optisk rent (+) norcisaprid sammen med et annet terapeutisk middel for fremstilling av et medikament

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20041166A NO20041166L (no) 1996-07-19 2004-03-19 Anvendelse av optisk rent (+) norcisaprid sammen med et annet terapeutisk middel for fremstilling av et medikament

Country Status (25)

Country Link
US (3) US5739151A (no)
EP (1) EP0896539B1 (no)
JP (1) JP3097697B2 (no)
KR (4) KR100399808B1 (no)
CN (1) CN1215992A (no)
AT (1) ATE197762T1 (no)
AU (1) AU3592097A (no)
BG (1) BG63190B1 (no)
BR (1) BR9708287A (no)
CA (1) CA2245768C (no)
CZ (1) CZ293478B6 (no)
DE (1) DE69703617T2 (no)
DK (1) DK0896539T3 (no)
ES (1) ES2152687T3 (no)
GR (1) GR3035460T3 (no)
HU (1) HUP9904360A3 (no)
IL (1) IL125703A0 (no)
IS (1) IS4820A (no)
NO (2) NO317178B1 (no)
NZ (1) NZ331291A (no)
PL (1) PL189610B1 (no)
PT (1) PT896539E (no)
SK (1) SK282673B6 (no)
TR (1) TR199801816T2 (no)
WO (1) WO1998003173A1 (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712293A (en) * 1995-06-07 1998-01-27 Sepracor, Inc. Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride
US6147093A (en) 1996-07-19 2000-11-14 Sepracor Inc. Methods for treating gastroesophageal reflux disease
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
KR100469030B1 (ko) * 1996-10-15 2005-01-31 얀센 파마슈티카 엔.브이. 시사프라이드의 합성방법
IL133225A (en) * 1997-07-11 2005-12-18 Janssen Pharmaceutica Nv (+)-Norcisapride useful for 5-HT3 and 5- HT4 mediated disorders
EP1468685A3 (en) * 1998-06-15 2004-12-15 Sepracor Inc. Use of optically pure (+)-norcisapride for treating apnea, bulimia and other disorders
EP1087765B1 (en) * 1998-06-15 2005-03-30 Sepracor Inc. Use of optically pure (-) norcisapride in the treatment of irritable bowel syndrome
CA2333666A1 (en) * 1998-06-15 1999-12-23 Sepracor Inc. Use of optically pure (+)-norcisapride for treating apnea, bulimia and other disorders
EP1464333A3 (en) * 1998-06-15 2004-12-15 Sepracor Inc. Use of optically pure (-) norcisapride in the treatment of apnea, bulimia, and other disorders
PL200132B1 (pl) * 1998-08-21 2008-12-31 Novartis Ag Zastosowanie 3-(5-metoksy-1H-indol-3-ilometyleno)-N-pentylokarbazyimidoamidu
US6353005B1 (en) 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
US6362202B1 (en) * 1999-03-02 2002-03-26 Sepracor Inc. Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
US6803387B1 (en) * 1999-03-19 2004-10-12 Abbott Gmbh & Co. Kg Treatment of neuropathic pain or fibromyalgia
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
EP1321142A1 (en) * 2001-12-21 2003-06-25 Novartis AG Solid pharmaceutical composition for oral administration of Tegaserod
FR2854072B1 (fr) * 2003-04-23 2006-08-04 Centre Nat Rech Scient Vecteur pour administration par voie orale
US8138204B2 (en) * 2004-01-07 2012-03-20 Aryx Therapeutics, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
US7176218B2 (en) * 2004-01-07 2007-02-13 Aryx Therapeutics Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
US8524736B2 (en) 2004-01-07 2013-09-03 Armetheon, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
US20090170899A1 (en) * 2004-09-14 2009-07-02 Guy Debonnel Stimulators of 5-HT4 receptors and uses thereof
DK1919909T3 (da) * 2005-08-31 2013-12-02 Armetheon Inc Syntesemetoder og mellemprodukter for stereoisomere forbindelser, der er anvendelige til behandling af gastrointestinale forstyrrelser og forstyrrelser i centralnervesystemet
US20080085915A1 (en) * 2006-06-23 2008-04-10 Cyrus Becker Compounds and methods for the treatment of gastrointestinal and central nervous system disorders
EP2488171A4 (en) 2009-10-16 2014-04-23 Epiomed Therapeutics Inc TREATMENT OF VOMITING
JP5890436B2 (ja) * 2011-02-25 2016-03-22 ユーハン・コーポレイションＹＵＨＡＮ Ｃｏｒｐｏｒａｔｉｏｎ ジアミノピリミジン誘導体及びその製造方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5137896A (en) * 1981-10-01 1992-08-11 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)benzamide derivatives
CA1183847A (en) * 1981-10-01 1985-03-12 Georges Van Daele N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US5057525A (en) * 1981-10-01 1991-10-15 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl) benzamide derivatives
US4962115A (en) * 1981-10-01 1990-10-09 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US5114714A (en) * 1990-11-29 1992-05-19 Sepracor, Inc. Methods of use and compositions of (r)-isoflurane and (r)-desflurane
US5114715A (en) * 1990-11-29 1992-05-19 Sepracor Inc. Methods of use and compositions of (s)-isoflurane and (s)-desflurane
JPH08502032A (ja) * 1992-07-07 1996-03-05 セプラコア インコーポレーテッド 胃食道逆流疾患およびその他の障害を治療するために▲（−）▼シサプリドを使用する方法
JPH08502031A (ja) * 1992-07-07 1996-03-05 セプラコア インコーポレーテッド 胃食道逆流疾患およびその他の障害を治療するために▲（＋）▼シサプリドを使用する方法
EP0707492A1 (en) * 1993-07-06 1996-04-24 Merck & Co. Inc. H 2? antagonist-gastrointestinal motility agent combinations
US5712293A (en) * 1995-06-07 1998-01-27 Sepracor, Inc. Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride

Also Published As

Publication number Publication date
IS4820A (is) 1998-08-10
BG102757A (en) 1999-08-31
SK123998A3 (en) 1999-03-12
PT896539E (pt) 2001-05-31
CA2245768A1 (en) 1998-01-29
NO20041166L (no) 2004-03-19
JPH11510828A (ja) 1999-09-21
SK282673B6 (sk) 2002-11-06
NO983636D0 (no) 1998-08-07
CZ293478B6 (cs) 2004-05-12
KR100328731B1 (ko) 2002-10-19
AU3592097A (en) 1998-02-10
NO317178B1 (no) 2004-09-06
BR9708287A (pt) 2000-01-18
KR100399808B1 (ko) 2003-09-29
ATE197762T1 (de) 2000-12-15
HUP9904360A2 (hu) 2000-05-28
CZ250898A3 (cs) 1999-04-14
US6114356A (en) 2000-09-05
GR3035460T3 (en) 2001-05-31
IL125703A0 (en) 1999-04-11
CA2245768C (en) 2003-09-30
CN1215992A (zh) 1999-05-05
TR199801816T2 (xx) 2000-10-23
JP3097697B2 (ja) 2000-10-10
KR100533237B1 (ko) 2005-12-05
BG63190B1 (bg) 2001-06-29
EP0896539A1 (en) 1999-02-17
NZ331291A (en) 2000-06-23
KR20040007505A (ko) 2004-01-24
ES2152687T3 (es) 2001-02-01
DK0896539T3 (da) 2001-02-19
KR20000064524A (ko) 2000-11-06
PL189610B1 (pl) 2005-08-31
US5877188A (en) 1999-03-02
PL335254A1 (en) 2000-04-10
HUP9904360A3 (en) 2001-07-30
US5739151A (en) 1998-04-14
WO1998003173A1 (en) 1998-01-29
DE69703617D1 (de) 2001-01-04
DE69703617T2 (de) 2001-04-12
EP0896539B1 (en) 2000-11-29
KR100422492B1 (ko) 2004-03-11

Similar Documents

Publication Publication Date Title
NO983636L (no) FremgangsmÕte for behandling av brekninger og sykdomstilstander i sentralnervesystemet ved anvendelse av optisk rent (+) norcisaprid
IS1904B (is) Hliðstæðar aðferðir við framleiðslu á nýjum (R)-5-karbamóýl-8-flúor-3-N,N-tvíútskiptum-amínó-3,4-díhýdró-2H-1-bensópýrönum
BR9810841A (pt) Inibidores de metaloprotease alicìclicos
BR9713186A (pt) Inibidores de metaloprotease 1,3-diheterocìclicos
MX9702865A (es) Agentes estrogenicos.
BG101806A (en) Indole derivatives as 5-ht receptor antagoniss
MY144483A (en) 1,2,3,4-tetrasubstituted indole for the treatment of respiratory diseases
AU3401797A (en) Compounds having effects on serotonin-related systems
EE04491B1 (et) (+)-nortsisapriidi kasutamine
DK0556332T3 (da) Substituerede tetrahydropyridiner og hydroxypiperidiner som midler til behandling af centralnervesystemet
EA199700151A1 (ru) Композиция для чрескожного введения
DE69914935D1 (de) 8-azabicyclo[3.2.1]okt-2-en- und -oktanderivate
NZ331683A (en) New indole and indazole compounds, a process for their preparation and pharmaceutical compositions containing them
MA26732A1 (fr) Composition pharmaceutique nouvelle comprenant un inhibiteur de nos, et procede pour sa preparation
MXPA02000330A (es) Pirrolidinas y piperidinas neurotroficas y composiciones y metodos relacionados.
BG105218A (en) The use of optically pure (+) norcisapride for treating gastro-esophageal reflux disease
ATE309811T1 (de) Analgetikum aus schlangengift
CA2296560A1 (en) Amino acid derivatives useful to treat stroke
DK0656209T3 (da) Melatoninderivater til anvendelse ved behandling af desynkroniseringsforstyrrelser
NO990450D0 (no) Behandling av sinnslidelser
ES2191170T3 (es) Nuevos (-)-enantiomeros de derivados de cis-3,4-cromano utiles en la prevencion y tratamiento de sindromes o enfermedades relacionadas con el estrogeno.
WO2004016604A3 (en) Azabicyclic compounds are central nervous system active agents
CY1106922T1 (el) Ενωσεις ισοκινολινυλ αροϋλ πυρρολης για την αγωγη των διαταραχων κεντρικου νευρικου συστηματος
AU6919398A (en) Heterocyclic compounds and their preparation and use
DK0777663T3 (da) Anvendelse af substituerede 6-amino-4H-pyraner